Asthma Trial, Recruiting NCT05274425 Sponsor: Novartis Pharmaceuticals Condition: Asthma
Back to Asthma

Asthma Trial, Recruiting

NCT05274425
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with asthma by a doctor, and whose doctor has prescribed them Enerzair inhalation capsules (a combination inhaler containing indacaterol acetate, glycopyrronium bromide, and mometasone furoate) used with a Breezhaler device, in line with the approved prescribing information
  • People who have been given a clear explanation of the study by the trial team and have signed a consent form agreeing to how their data will be collected and used

Who may not be able to join:

  • People who have a known allergic or sensitivity reaction to Enerzair or any of its ingredients
  • People who have hereditary conditions affecting how the body processes certain sugars (such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption), as Enerzair contains lactose
  • People who are currently experiencing sudden or severe asthma symptoms, including episodes of airway tightening that require a fast-acting reliever inhaler
  • People who are already taking part in another clinical trial that involves a treatment or intervention

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
9 May 2022
Est. completion
11 March 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Incidence of adverse events and serious adverse events; Incidence of unexpected adverse events and unexpected serious adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov